Results of evaluation of the effectiveness of the drug Cellex in patients with small vessel disease

• Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Vol. 123; no. 1; p. 67
• Main Authors: Kamchatnov, P R, Abusueva, B A, Khanmurzaeva, S B, Mityaeva, E V, Chipova, D T, Malashenkov, N D
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2023
• Subjects: Brain; Cerebral Small Vessel Diseases - drug therapy; Cognitive Dysfunction; Humans; Inflammation; Neuropsychological Tests; Stroke; neurometabolic therapy; treatment; cognitive impairment; Cellex; small cerebral vessel disease
• ISSN: 1997-7298
• DOI: 10.17116/jnevro202312301167

To study the effect of the drug Cellex on the severity of cognitive impairment in patients with small vessel disease (SVD).
A non-interventional observational controlled prospective observational study in parallel groups was conducted. 118 patients with CHEM who received unified therapy were under observation. Group 1 consisted of 40 patients who, in addition to basic therapy, received 10 injections of Cellex subcutaneously (0.2 ml 1 time/day), group 2 - 39 patients who received 2 courses of injections of Cellex subcutaneously (0.1 ml 1 time/day) with an interval of one month, patients 3-both groups (
=39) received only basic therapy. The examination included an assessment of the clinical status and neuropsychological testing (the MOS questionnaire and the clock drawing test - TRCH), analysis of the results of MRI of the brain. The blood levels of homocysteine (HC), C-reactive protein (CRP), asymmetric dimethylarginin (ADMA), and von Willebrand factor (FW) were determined in dynamics.
A statistically significant improvement in the performance of the MoCA and TRP questionnaire tests in groups 1 and 2 was demonstrated, with a more pronounced and persistent effect in patients who received repeated courses of treatment. Clinical improvement was accompanied by normalization of the concentration of studied markers of inflammation (CRP) and endothelial dysfunction (HC, ADMA, FW) in the blood, while the dynamics was most pronounced in patients of group 2. The treatment was characterized by good tolerability, low frequency and insignificant severity of adverse events.
The drug Cellex has demonstrated significant effectiveness in the treatment of patients with SVD with cognitive impairment, against the background of treatment, there was a decrease in markers of inflammation and endothelial dysfunction, therapy was characterized by good tolerability.